Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect
نویسندگان
چکیده
منابع مشابه
Bosentan therapy for portopulmonary hypertension.
The dual endothelin receptor antagonist bosentan has been approved in several countries for pulmonary arterial hypertension, and patients with portopulmonary hypertension (PPHTN) have not specifically been excluded. However, no data have been published on the efficacy and safety of bosentan in this patient population. Here, the first clinical experiences with bosentan in patients with Child A c...
متن کاملExperience with inhaled iloprost and bosentan in portopulmonary hypertension.
Novel treatments, such as prostanoids or endothelin receptor antagonists, have been introduced for various forms of pulmonary arterial hypertension, but the long-term effects of these treatments on portopulmonary hypertension (PPHT) are unknown. In a retrospective analysis, the present authors assessed the safety and efficacy of inhaled iloprost, a prostacyclin analogue, and bosentan, an endoth...
متن کاملPharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4-5 weeks of S+A or S+B treatment in patients with pulmonary arterial hypertension. The area under the plasma concentration-time curve of silde...
متن کاملEfficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
Data on treatment of patients with portopulmonary hypertension (PoPH) are limited, as they are usually excluded from randomised controlled trials with pulmonary arterial hypertension (PAH)-specific therapies. This study investigated the short- and long-term efficacy/safety of bosentan in these patients, as well as its pharmacokinetics. All 34 consecutive patients with PoPH treated with first-li...
متن کاملHow should we treat portopulmonary hypertension?
T he development of pulmonary arterial hypertension in the setting of advanced liver disease (portopulmonary hypertension (POPH)) has certainly captured the attention of all liver transplant centres, but why? For patients with moderate-to-severe POPH (mean pulmonary artery pressure (mPAP) .35 mmHg and pulmonary vascular resistance (PVR) .400 dyne?s?cm-5), the risk of intra-operative death and p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Heart Journal
سال: 2015
ISSN: 1349-2365,1349-3299
DOI: 10.1536/ihj.15-007